Last updated: February 13, 2026
Summary:
NDC 51672-4039 is the drug Invega Trinza (paliperidone palmitate), a long-acting injectable antipsychotic primarily used to treat schizophrenia. Market dynamics for Invega Trinza reflect factors such as rising mental health awareness, prescription trends, regulatory changes, and pricing strategies.
Product Overview:
- Indication: Schizophrenia maintenance therapy
- Formulation: Long-acting intramuscular injection
- Dosing Schedule: Every three months
- Manufacturer: Janssen Pharmaceuticals (Johnson & Johnson subsidiary)
- Approval Date: Approved by the FDA in 2015
Market Size and Demand Drivers
Global and U.S. Market:
The antipsychotic market, particularly long-acting injectables (LAIs), is growing due to increasing schizophrenia diagnosis rates, patient compliance issues with oral medication, and expanding approval for LAIs.
- U.S. Market Size (2022): Estimated at USD 1.2 billion for long-acting antipsychotics [1].
- Growth Rate: Expected CAGR of roughly 4.5% through 2027 [2].
Key Demand Drivers:
- Elevated emphasis on treatment adherence
- Growing acceptance in clinical guidelines
- Expansion into additional indications, such as bipolar disorder (off-label)
- Competitive landscape with drugs like Risperdal Consta, Abilify Maintena, and Aristada
Market Penetration:
Invega Trinza captured approximately 20% of the LAI schizophrenia segment in the U.S. by 2021, reflecting strong prescriber adoption, though competition remains stiff.
Pricing Trends and Projections
Current List Price:
As of late 2022, the average wholesale price (AWP) for Invega Trinza stands around USD 7,500 per 3-month injection. Actual pricing varies by pharmacy and insurance negotiations.
| Pricing Aspect |
Value |
Notes |
| List Price per injection |
USD 7,500 |
Reflects baseline price, prices may vary nationally |
| Average Reimbursement |
USD 7,200 |
After rebates and discounts |
| Out-of-pocket cost |
USD 50-200 (estimated) |
Depends on insurance plan and copays |
Historical Price Trends:
Between 2019 and 2022, Invega Trinza's price remained relatively stable, with minor adjustments due to inflation and reimbursement shifts for the broader LAI class.
Future Price Projections (2023-2027):
Assuming inflation-adjusted increases aligned with healthcare cost trends, prices are projected to grow at an annual rate of 2-3%, reaching approximately USD 7,700 - USD 8,200 per 3-month dose by 2027.
Factors Influencing Price Movements:
- Patent protection until at least 2028, limiting generic competition
- Potential biosimilar development or FDA approval of alternatives
- Market entry of next-generation LAIs with improved delivery systems
- Reimbursement negotiations and insurer formulary decisions
Competitive Landscape and Impact on Pricing
Major Competitors:
- Risperdal Consta (risperidone)
- Abilify Maintena (aripiprazole)
- Aristada (aripiprazole lauroxil)
Market Share Shifts:
Invega Trinza's three-month dosing offers an advantage over competitors with shorter dosing intervals, influencing price premiums.
Biosimilar and Generic Threats:
No biosimilar or generic versions available as of 2023 due to patent protections. Patent expiration potentially available around 2028, which could reduce prices significantly.
Conclusion
Invega Trinza maintains a premium price due to formulation advantages, patent exclusivity, and clinical preference for long-acting injectables. With ongoing demand and limited competition, prices are expected to grow modestly until patent expiration, after which substantial price reductions are probable.
Key Takeaways
- The current average wholesale price for Invega Trinza is approximately USD 7,500 per dose.
- Market growth driven by expanding LAI use and increasing schizophrenia prevalence.
- Price projections indicate incremental growth of 2-3% annually through 2027.
- Patent protection prolongs market exclusivity, delaying price erosion.
- Entry of biosimilars or generics around 2028 could drastically reduce prices.
FAQs
1. How does Invega Trinza compare price-wise to other LAIs?
It is priced higher than some oral antipsychotics and shorter-acting injectables, reflecting its extended dosing schedule and formulation. Its price per dose is also competitive within the LAI segment.
2. What factors could influence a change in Invega Trinza’s price?
Patent expiration, regulatory shifts, market penetration, competitive biosimilar development, and reimbursement negotiations affect prices.
3. What is the impact of insurance coverage on patient costs?
Insurance negotiations lower the out-of-pocket costs, which typically range from USD 50-200 per dose, depending on plan specifics.
4. Are there any upcoming regulatory or patent expirations?
Patent protection extends until at least 2028, after which generic or biosimilar options could reduce prices.
5. How does the demand forecast affect market projections?
Increased prescription rates due to clinical guidelines and patient adherence will sustain or increase demand, supporting stable or rising prices.
References
[1] MarketWatch, "Long-Acting Antipsychotics Market Size," 2022.
[2] GlobalData, "Antipsychotics Market CAGR," 2022.
[3] FDA, “Invega Trinza Approval,” 2015.
[4] IQVIA, "Prescription Trends," 2022.
